Background: Caffeine and cannabis are globally consumed and abused psychoactive substances. While caffeine is legally used in various forms, including in tea and coffee as beverages, it is also consumed in soda and energy drinks as additives. Cannabis, on the other hand, is considered illegal in most countries; albeit, it is being consumed globally particularly by adolescents. Purpose: The adolescent stage marks a critical stage of brain development and maturation. Influences of agents on the brain at this stage may affect neuronal structural and functional attributes. To this end, the current experiment considered the effects of cannabis and caffeine on selected key neurotransmitters and enzymes in the brain tissues after regimented caffeine and cannabis treatment for 21 days. Methods: A total of 72 juvenile Wistar rats that were approximately 40 days old were divided into 6 groups A-F. The group A served as the control. Other groups were administered various dosages of caffeine or cannabis in distilled water, using oral gavages as follows: group B animals received 100 mg/kg body weight of caffeine, group C animals received 50 mg/kg body weight of caffeine, group D animals received 500 mg/kg body weight of cannabis, group E animals received 200 mg/kg body weight of cannabis, and group F received a low dose of cannabis (200 mg/kg body weight) plus a low dose of caffeine (50 mg/kg body weight). The animals were killed by cervical dislocation 24 h after the last administration. The brain tissues were excised and homogenized. The enzymes cytochrome C oxidase and glucose-6-phosphate dehydrogenase were assayed to observe tissue energy metabolism while the neurotransmitters gamma-amino butyric acid (GABA), glutamate, and dopamine were assayed to observe the effects of the psychoactive substances on their activities relative to mental activities. Results: GABA, glutamate, and dopamine were generally higher in the treated groups of animals. The levels of G-6-PDH were higher in all treated animals' brains. Caffeine produced quite more significant effects relative to cannabis and the combination of both increased the level of G-6-PDH significantly. Conclusion: Results showed that caffeine and cannabis influenced the activities of the enzymes and neurotransmitters in the brain. Both stimulants altered brain chemistry relative to the tested enzymes and neurotransmitters.

Keywords:
Caffeine, Cannabis, Cytochrome C oxidase, Glucose-6-phosphate dehydrogenase, Gamma-amino butyric acid, Glutamate, Dopamine, Brain
1.
Nehlig A, Daval JL, Debry G: Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992;17:139-170.
2.
Nehlig A: Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci Biobehav Rev 1999;23:563-576.
3.
Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
4.
Temple JL: Caffeine use in children: what we know, what we have left to learn, and why we should worry. Neurosci Biobehav Rev 2009;33:793-806.
5.
Brice C, Smith A: The effects of caffeine on simulated driving, subjective alertness and sustained attention. Hum Psychopharmacol 2001;16:523-531.
6.
Childs E, de Wit H: Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) 2006;185:514-523.
7.
Roehrs T, Roth T: Caffeine: sleep and daytime sleepiness. Sleep Med Rev 2008;12:153-162.
8.
Hughes JR, Hale KL: Behavioral effects of caffeine and other methylxanthines on children. Exp Clin Psychopharmacol 1998;6:87-95.
9.
Rogers PJ, Heatherley SV, Hayward RC, Seers HE, Hill J, Kane M: Effects of caffeine and caffeine withdrawal on mood and cognitive performance degraded by sleep restriction. Psychopharmacology (Berl) 2005;179:742-752.
10.
Smith A: Effects of caffeine on human behavior. Food Chem Toxicol 2002;40:1243-1255.
11.
Mahmoud AE: Marijuana and the Cannabinoids. Humana Press, p 8. ISBN 1-58829-456-0 (retrieved May 2, 2011).
12.
Hazekamp A, Grotenhermen F: Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 2010;5:1-21.
13.
Wade L: Hardcore Pot Smoking Could Damage the Brain's Pleasure Center. Science, 2014. http://www.sciencemag.org/news (accessed June 14, 2016).
14.
NIH: National Institute on Drug Abuse. Marijuana, 2007. www.drugabuse.gov (accessed June 15, 2016).
15.
Lemberg MR: Cytochrome oxidase. Physiol Rev 1969;49:48-121.
16.
SIGMA-ALDRICH: Enzymatic Method for Determining Glutamate (Glutamate Assay), 2017. http://www.sigmaaldrich.com.
17.
Anderson W, Nordlie R: Glucose dehydrogenase activity of yeast glucose 6-phosphate dehydrogenase. I. Selective stimulation by bicarbonate, phosphate, and sulfate. Biochemistry 1968;7:1479-1485.
18.
Elisa GABA Protocol: Elisa Enzyme-linked ImmunosorbentAssay Kit for Gamma-Aminobutyric Acid (GABA). Houston, 2015. www.cloud-clone.us.
19.
SIGMA-ALDRICH: Enzymatic Method for Determining Glutamate (Glutamate assay). 2016. http://www.sigmaaldrich.com/technical-documents/protocols/biology/glutamate-assay-kit-mak004.html.
20.
Atack CV: The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay. Br J Pharmacol 1973;48:699-714.
21.
Roca DJ, Schiller GD, Farb DH: Chronic caffeine or theophylline exposure reduces gamma-aminobutyric acid/benzodiazepine receptor site interactions. Mol Pharmacol 1988;33:481-485.
22.
Shi D, Nikodijević O, Jacobson KA, Daly JW: Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. Cell Mol Neurobiol 1993;13:247-261.
23.
Fallows Z: Medlinks - Center for Health Promotion and Wellness at MIT Medical. http://ocw.mit.edu (accessed June 17, 2016).
24.
Mental Health Daily: High Dopamine Levels: Symptoms and Adverse Reactions. http://mentalhealthdaily.com/2015 (accessed June 17, 2016).
25.
Persad, LAB: Energy drinks and the neurophysiological impact of caffeine. Front Neurosci 2011;5:116.
26.
Myhrer T: Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev 2003;41:268-287.
27.
Acquas E, Tanda G, Di Chiara G: Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacology 2002;27:182-193.
28.
Schlicker E, Kathmann M: Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001;22:565-572.
29.
Gill EW, Paton WD, Pertwee RG: Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 1970;229:134-136.
30.
Roth SH: Stereospecific presynaptic inhibitory effect of delta9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol 1978;56:968-975.
31.
Iversen L: Cannabis and the brain. Brain 2003;126(pt 6):1252-1270.
32.
Joy JE, Watson SJ, Benson JA: Marijuana and Medicine, Assessing the Science Base. Washington, National Academy Press, 1999.
33.
Robson P: Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001;178:107-115.
34.
Piomelli D, Giuffrida A, Calignano A, et al: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000;21:218-224.
35.
Pollak DI, Furth D, Xuan Y, Johansson Y, Pozzi L, Silberberg G, Carlen M, Meletis K: A whole-brain atlas of inputs to serotonergic neurons of the dorsal and median raphe nuclei. Neuron 2014;83:663-678.
36.
Bouckaert F, Sienaert P, Obbels J, Dols A, Vandenbulcke M, Stek M, Bolwig T: ECT: its brain enabling effects: a review of electroconvulsive therapy-induced structural brain plasticity. J ECT 2014;30:143-151.
37.
Tian WN, Braunstein LD, Pang J, Stuhlmeier KM, Xi QC, Tian X, Stanton RC: Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem 1998;273:10609-10617.
38.
Wang YP, Zhou LS, Zhao YZ, Wang SW, Chen LL, Liu LX, Ye D: Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J 2014;33:1304-1320.
39.
Yee GM, Tolman WB: Chapter 5, section 2.3: iron-porphyrin/copper complexes as cytochrome C oxidase models'; in Peter MH, Kroneck, Martha E, Sosa T (eds): Sustaining Life on Planet Earth: Metalloenzymes Mastering Dioxygen and Other Chewy Gases. Metal Ions in Life Sciences15. Springer, 2015, pp 153-157.
40.
Yoshikawa S, Shimada A, Shinzawa-Itoh K: Chapter 4: respiratory conservation of energy with dioxygen: cytochrome C oxidase'; in Kroneck PMH, Martha E, Sosa T (eds): Sustaining Life on Planet Earth: Metalloenzymes Mastering Dioxygen and Other Chewy Gases. Metal Ions in Life Sciences 15. Springer, 2015, pp 89-130.
41.
Khalimonchuk O, Rödel G: Biogenesis of cytochrome C oxidase. Mitochondrion 2005;5:363-388.
42.
Fontanesi F, Soto IC, Horn D, Barrientos A: Assembly of mitochondrial cytochrome c-oxidase, a complicated and highly regulated cellular process. Am J Physiol Cell Physiol 2006;291:C1129-C1147.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.